Skin test may personalize asthma care for kids
NCT ID NCT04699604
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether a skin test that measures histamine response can help doctors decide if adding an antihistamine (Levocetirizine) to standard asthma treatment improves control in children aged 6-17 with allergic asthma. About 300 African American/Black and Caucasian/White children will be randomly assigned to receive either the antihistamine or a placebo for 6 weeks, then switch. The goal is to see if the skin test predicts who benefits most from antihistamine therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Levocetirizine (Xyzal)
- What this could lead to
- If successful, this could provide a simple skin test to identify which children with allergic asthma would benefit from adding an antihistamine to their current treatment.
- What could go wrong
- This is a Phase 3 trial, but it is still testing a biomarker approach. The antihistamine may not improve asthma control for all children, and results may vary by race or phenotype.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Allergy shots may unlock better asthma control by targeting hidden immune signals
- New asthma drug JYB1904 shows promise in early trial
- Cleveland clinic launches asthma research to develop better tests and treatments
- Cat allergy treatment gets a needle upgrade: fewer shots, same hope
- Biosimilar switch for asthma and hives under Real-World study
- Massive study tracks 1,000 people to unlock secrets of eczema remission